Real World Evidence Marches Forward in Drug Development

Ulrich Neumann

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm on real-world evidence (RWE) and its adoption in the drug development process. While the collection of real-world data (RWD) and use of RWE is not new, they are now poised to have a profound impact on our industry.  Today, it […]

Read More
Topics: Evidence and Market Access